Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

BACKGROUND: Myelofibrosis (MF) is associated with a variety of burdensome symptoms and reduced survival compared with age-/sex-matched controls. This analysis evaluated the long-term survival benefit with ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor, in patients with intermediate-2 (int-2) or h...

詳細記述

保存先:
書誌詳細
出版年:J Hematol Oncol
主要な著者: Verstovsek, Srdan, Gotlib, Jason, Mesa, Ruben A., Vannucchi, Alessandro M., Kiladjian, Jean-Jacques, Cervantes, Francisco, Harrison, Claire N., Paquette, Ronald, Sun, William, Naim, Ahmad, Langmuir, Peter, Dong, Tuochuan, Gopalakrishna, Prashanth, Gupta, Vikas
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2017
主題:
Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5622445/
https://ncbi.nlm.nih.gov/pubmed/28962635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-017-0527-7
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料